Loading video...

Video Failed to Load

Go Home

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as...

PureTechH's profile picture

PureTech

4,263 subscribers

10,892 views • 1 year ago •via X (Twitter)

Health & WellnessScience & TechnologyNews & Politics#IPF
LIVE

Anya Rossi• Live Now

Private livecam show

1 Comments

jingscrivens's profile picture
jingscrivens1 year ago

Great of luck for 2025

Related Videos

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:
0:45

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Kymera Therapeutics

21,055 views • 1 month ago

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:
1:29

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:

Breakthrough T1D

42,494 views • 1 year ago

AI DISCOVERS REVOLUTIONARY NEW WAY TO REVERSE LUNG DAMAGE An AI system didn’t just design a new drug for pulmonary fibrosis; it first figured out which protein was causing the damage (TNIK), then designed a molecule to shut it down. In a 12-week trial, patients on the highest dose gained almost 100 ml of lung capacity, something that's never been achieved before with any other drug. For a disease that usually only gets worse, that’s like hitting rewind on the damage. Source: Nature Medicine
1:49

AI DISCOVERS REVOLUTIONARY NEW WAY TO REVERSE LUNG DAMAGE An AI system didn’t just design a new drug for pulmonary fibrosis; it first figured out which protein was causing the damage (TNIK), then designed a molecule to shut it down. In a 12-week trial, patients on the highest dose gained almost 100 ml of lung capacity, something that's never been achieved before with any other drug. For a disease that usually only gets worse, that’s like hitting rewind on the damage. Source: Nature Medicine

Mario Nawfal

29,349 views • 10 months ago

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology
2:02

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,395 views • 8 months ago

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:
2:23

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:

Recursion

11,944 views • 6 months ago

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:
1:29

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

Recursion

255,879 views • 8 months ago

Today, we take the next step in Verve’s journey: the acquisition by Eli Lilly and Company is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could one day offer durable protection from atherosclerotic cardiovascular disease. Lilly shares our vision of changing the treatment paradigm for cardiovascular disease. We believe Verve + Lilly is a uniquely powerful combination — one that brings together complementary strengths to deliver on the promise of single-course gene editing medicines for millions around the world. To the Verve team: thank you. Your drive, grit, and heart made this possible. And to the investigators and patients who have participated in our trials — we are deeply grateful. $VERV $LLY
2:24

Today, we take the next step in Verve’s journey: the acquisition by Eli Lilly and Company is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could one day offer durable protection from atherosclerotic cardiovascular disease. Lilly shares our vision of changing the treatment paradigm for cardiovascular disease. We believe Verve + Lilly is a uniquely powerful combination — one that brings together complementary strengths to deliver on the promise of single-course gene editing medicines for millions around the world. To the Verve team: thank you. Your drive, grit, and heart made this possible. And to the investigators and patients who have participated in our trials — we are deeply grateful. $VERV $LLY

Sek Kathiresan MD

30,204 views • 1 year ago

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.
1:55

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.

CBS News

19,903 views • 4 months ago

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone that will not only transform the field of interventional cardiology but, most importantly, will change the lives of countless patients who have been waiting for a viable treatment option. Slides presented as LBCT #TCT2025 today and link to our manuscript published The Lancet today are included. Thank you to all the people who worked with us for a decade to make this happen! Dave Daniels Mayo Clinic CV
2:19

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone that will not only transform the field of interventional cardiology but, most importantly, will change the lives of countless patients who have been waiting for a viable treatment option. Slides presented as LBCT #TCT2025 today and link to our manuscript published The Lancet today are included. Thank you to all the people who worked with us for a decade to make this happen! Dave Daniels Mayo Clinic CV

Mayra Guerrero, MD

20,941 views • 9 months ago

Today, Alhamdolillah, we mark a proud and historic milestone in our journey toward a healthier and safer Punjab. With 90% HPV vaccination coverage, the future of over 6.7 million daughters across the province has been safeguarded from a life-threatening disease. This achievement is more than a number. It is a powerful step toward protecting the health and dignity of our girls. My heartfelt congratulations to the EPI team, the Health Department, and all those who worked tirelessly on the ground. Your dedication has set a new standard for public health in Pakistan. To the parents of Punjab: thank you for your confidence, your cooperation, and your belief in this cause. Your trust made this possible. As a woman, a mother, and your Chief Minister, I consider the protection of every daughter a deeply personal victory, one that fills me with pride and renewed purpose. Together, we are building a Punjab where no daughter is left unprotected. Onward, with faith, with resolve, and with hope.
1:24

Today, Alhamdolillah, we mark a proud and historic milestone in our journey toward a healthier and safer Punjab. With 90% HPV vaccination coverage, the future of over 6.7 million daughters across the province has been safeguarded from a life-threatening disease. This achievement is more than a number. It is a powerful step toward protecting the health and dignity of our girls. My heartfelt congratulations to the EPI team, the Health Department, and all those who worked tirelessly on the ground. Your dedication has set a new standard for public health in Pakistan. To the parents of Punjab: thank you for your confidence, your cooperation, and your belief in this cause. Your trust made this possible. As a woman, a mother, and your Chief Minister, I consider the protection of every daughter a deeply personal victory, one that fills me with pride and renewed purpose. Together, we are building a Punjab where no daughter is left unprotected. Onward, with faith, with resolve, and with hope.

Maryam Nawaz Sharif

53,735 views • 10 months ago

🐶 Doing Only Good with Dogecoin! 🐶 We’re excited to share that 100% of our Dogecoin $DOGE sales from June and July were donated to Animal Haven Animal Shelter, a wonderful organization in New York that changes animals lives. Animal Haven is a safe haven, providing: 🐈 Rescues for abandoned pets. 💝 Loving care and medical treatment for animals awaiting adoption. 🏡 Forever homes for those who need them most. Thank you to everyone who joined us in demonstrating the incredible impact of the Dogecoin community, for the love of animals and Pizza. 🍕🐕
0:25

🐶 Doing Only Good with Dogecoin! 🐶 We’re excited to share that 100% of our Dogecoin $DOGE sales from June and July were donated to Animal Haven Animal Shelter, a wonderful organization in New York that changes animals lives. Animal Haven is a safe haven, providing: 🐈 Rescues for abandoned pets. 💝 Loving care and medical treatment for animals awaiting adoption. 🏡 Forever homes for those who need them most. Thank you to everyone who joined us in demonstrating the incredible impact of the Dogecoin community, for the love of animals and Pizza. 🍕🐕

Williamsburg Pizza

21,702 views • 1 year ago

90% of people aren’t getting enough choline, and it’s quietly driving up their risk for heart disease and dementia Even slight deficiencies in choline can elevate homocysteine levels—a biomarker strongly linked to cardiovascular disease and cognitive decline Choline is also vital for brain function and development In fact, a randomized controlled trial found that pregnant women who increased their daily choline intake from roughly 500 milligrams (the recommended amount) to about 900 milligrams had children who scored dramatically higher on IQ and cognitive function tests Fortunately, eating around ~3 eggs per day or supplementing with phosphatidylcholine can correct this deficiency
2:42

90% of people aren’t getting enough choline, and it’s quietly driving up their risk for heart disease and dementia Even slight deficiencies in choline can elevate homocysteine levels—a biomarker strongly linked to cardiovascular disease and cognitive decline Choline is also vital for brain function and development In fact, a randomized controlled trial found that pregnant women who increased their daily choline intake from roughly 500 milligrams (the recommended amount) to about 900 milligrams had children who scored dramatically higher on IQ and cognitive function tests Fortunately, eating around ~3 eggs per day or supplementing with phosphatidylcholine can correct this deficiency

FoundMyFitness Clips

39,362 views • 1 year ago

Dear friends, supporters, and fellow Edolites, I am thrilled and honoured to announce our victory in the Labour Party governorship primary elections in Edo State! Your unwavering support has been the cornerstone of our success, and for that, I extend my deepest gratitude. This triumph is not merely a personal achievement but a testament to the strength of our shared aspirations for a better Edo state. Together, as a united community, we've demonstrated that there are no limits to what we can achieve when we work towards a common purpose. To the members of the Labour Party who participated in the primary elections, thank you for your trust and confidence in my leadership. I am fully aware of the responsibilities that come with this victory and am committed to representing your interests with the utmost dedication and integrity. As we celebrate this milestone, let's also reflect on the journey ahead. Our victory is a promise to the people of Edo State—a commitment to work tirelessly, listen attentively, and lead with transparency and accountability. Together, we will build a future that we can all be proud of—a prosperous, inclusive, and united Edo State. With heartfelt gratitude, Olumide Osaigbovo Akpata
1:57

Dear friends, supporters, and fellow Edolites, I am thrilled and honoured to announce our victory in the Labour Party governorship primary elections in Edo State! Your unwavering support has been the cornerstone of our success, and for that, I extend my deepest gratitude. This triumph is not merely a personal achievement but a testament to the strength of our shared aspirations for a better Edo state. Together, as a united community, we've demonstrated that there are no limits to what we can achieve when we work towards a common purpose. To the members of the Labour Party who participated in the primary elections, thank you for your trust and confidence in my leadership. I am fully aware of the responsibilities that come with this victory and am committed to representing your interests with the utmost dedication and integrity. As we celebrate this milestone, let's also reflect on the journey ahead. Our victory is a promise to the people of Edo State—a commitment to work tirelessly, listen attentively, and lead with transparency and accountability. Together, we will build a future that we can all be proud of—a prosperous, inclusive, and united Edo State. With heartfelt gratitude, Olumide Osaigbovo Akpata

Olumide Akpata

152,573 views • 2 years ago

It is with incredible honor to receive the prestigious Travvy Award for Executive of the Year. This award stands as a testament to the tireless work of our entire team at Sandals Resorts and Beaches Resorts and the progressive innovations we've embraced, resulting in a total of six accolades. We are a company profoundly committed to sharing our beautiful part of the planet with guests from around the world. Tourism fuels the economies of the Caribbean, and travel advisors are critical to the region’s success. Together with our esteemed partners, devoted travel agents, and trusted collaborators, we've set new standards in the realm of luxury travel and innovation, propelling the Caribbean islands onto the global stage. And to my team, there is no accolade I receive that you are not part of. I thank you for your dedication and incredibly hard work that has allowed us to pursue and expand upon the dreams we know are possible for the people and the places we love. I couldn't be more proud of what we have achieved. A heartfelt thank you to TravelPulse and #agentathome for hosting an unforgettable evening. #GetCloserToTheCaribbean #YourCaribbeanPlayground
1:07

It is with incredible honor to receive the prestigious Travvy Award for Executive of the Year. This award stands as a testament to the tireless work of our entire team at Sandals Resorts and Beaches Resorts and the progressive innovations we've embraced, resulting in a total of six accolades. We are a company profoundly committed to sharing our beautiful part of the planet with guests from around the world. Tourism fuels the economies of the Caribbean, and travel advisors are critical to the region’s success. Together with our esteemed partners, devoted travel agents, and trusted collaborators, we've set new standards in the realm of luxury travel and innovation, propelling the Caribbean islands onto the global stage. And to my team, there is no accolade I receive that you are not part of. I thank you for your dedication and incredibly hard work that has allowed us to pursue and expand upon the dreams we know are possible for the people and the places we love. I couldn't be more proud of what we have achieved. A heartfelt thank you to TravelPulse and #agentathome for hosting an unforgettable evening. #GetCloserToTheCaribbean #YourCaribbeanPlayground

Adam Stewart

16,435 views • 2 years ago

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:
0:20

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,887 views • 1 year ago

It's not uncommon to find 15, or even 50, different organizations dedicated to a single rare disease. This is without a doubt holding the rare disease community back. The reality is that compared to more common diseases, rare diseases already face significant hurdles in accessing resources. This scarcity is amplified by the fragmentation of groups. Each organization, operating in isolation, struggles to gather sufficient patient data and biospecimens, which are crucial for advancing research and treatment options. Imagine the potential if these groups could unite their efforts. By combining resources, sharing data, and collaborating on research, we could accelerate progress in ways that are currently out of reach. How can we foster greater unity in the rare disease community? What steps can we take to ensure that every organization, family, and patient is part of a larger, more effective network? #MedTwitter
0:33

It's not uncommon to find 15, or even 50, different organizations dedicated to a single rare disease. This is without a doubt holding the rare disease community back. The reality is that compared to more common diseases, rare diseases already face significant hurdles in accessing resources. This scarcity is amplified by the fragmentation of groups. Each organization, operating in isolation, struggles to gather sufficient patient data and biospecimens, which are crucial for advancing research and treatment options. Imagine the potential if these groups could unite their efforts. By combining resources, sharing data, and collaborating on research, we could accelerate progress in ways that are currently out of reach. How can we foster greater unity in the rare disease community? What steps can we take to ensure that every organization, family, and patient is part of a larger, more effective network? #MedTwitter

David Fajgenbaum, MD

27,305 views • 2 years ago

LOCK THEM UP AND THROW AWAY THE KEY The brilliant Dr Jeyanthi Kunadhasan testifies before an Australian Senate Committee that in Pfizer’s own clinical trial there were more deaths in the vaccinated group than the placebo group. For the TGA to grant approve to a new drug which had more deaths in the treatment group than the placebo group is beyond inconceivable, it was criminally negligent. And their excuse for doing so, was the claim the guesswork that the deaths in the vaccinated group where not related to the vaccine - yet many of these were unexplained sudden deaths for which no autopsy was performed. So their excuse that the deaths in the vaccinated group where not related to the vaccine was made without any evidence - which was also criminally negligent. And now we have tens of thousands of excess dead Australians - exactly what the results of the Pfizer trial suggested would happen. So it’s beyond criminal negligence- it’s mass negligent homicide. And to think they forced Australians to inject this stuff, knowing full well that Pfizer’s trial indicated that increase your risk of death. Forget the Royal Commission, we need to go straight to Nuremberg 2.0
2:24

LOCK THEM UP AND THROW AWAY THE KEY The brilliant Dr Jeyanthi Kunadhasan testifies before an Australian Senate Committee that in Pfizer’s own clinical trial there were more deaths in the vaccinated group than the placebo group. For the TGA to grant approve to a new drug which had more deaths in the treatment group than the placebo group is beyond inconceivable, it was criminally negligent. And their excuse for doing so, was the claim the guesswork that the deaths in the vaccinated group where not related to the vaccine - yet many of these were unexplained sudden deaths for which no autopsy was performed. So their excuse that the deaths in the vaccinated group where not related to the vaccine was made without any evidence - which was also criminally negligent. And now we have tens of thousands of excess dead Australians - exactly what the results of the Pfizer trial suggested would happen. So it’s beyond criminal negligence- it’s mass negligent homicide. And to think they forced Australians to inject this stuff, knowing full well that Pfizer’s trial indicated that increase your risk of death. Forget the Royal Commission, we need to go straight to Nuremberg 2.0

Craig Kelly:🇦🇺Foundation for Economic Education

262,856 views • 2 years ago